大腸癌:治療薬開発パイプライン分析

◆英語タイトル:Colorectal Cancer - Pipeline Review, H2 2017
◆商品コード:GMDHC10020IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年12月29日
◆ページ数:1962
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥535,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD7,500 ⇒換算¥802,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における大腸癌の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・大腸癌の概要
・大腸癌治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・大腸癌パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・大腸癌治療薬開発に取り組んでいる企業:企業別製品パイプライン
・大腸癌治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Colorectal Cancer – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer – Pipeline Review, H2 2017, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 26, 110, 143, 11, 175, 29 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 20, 9, 33 and 4 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 11
Colorectal Cancer – Overview 12
Colorectal Cancer – Therapeutics Development 13
Colorectal Cancer – Therapeutics Assessment 70
Colorectal Cancer – Companies Involved in Therapeutics Development 100
Colorectal Cancer – Drug Profiles 211
Colorectal Cancer – Dormant Projects 1872
Colorectal Cancer – Discontinued Products 1891
Colorectal Cancer – Product Development Milestones 1896
Appendix 1906

List of Tables
Number of Products under Development for Colorectal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by 3SBio Inc, H2 2017
Colorectal Cancer - Pipeline by 4SC AG, H2 2017
Colorectal Cancer - Pipeline by AB Science SA, H2 2017
Colorectal Cancer - Pipeline by AbbVie Inc, H2 2017
Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2017
Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2017
Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2017
Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Colorectal Cancer - Pipeline by AlfaSigma SpA, H2 2017
Colorectal Cancer - Pipeline by Allinky Biopharma, H2 2017
Colorectal Cancer - Pipeline by amcure GmbH, H2 2017
Colorectal Cancer - Pipeline by Amgen Inc, H2 2017
Colorectal Cancer - Pipeline by Amunix Operating Inc, H2 2017
Colorectal Cancer - Pipeline by Antibe Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by APEIRON Biologics AG, H2 2017
Colorectal Cancer - Pipeline by Apexigen Inc, H2 2017
Colorectal Cancer - Pipeline by Aphios Corp, H2 2017
Colorectal Cancer - Pipeline by Aposense Ltd, H2 2017
Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by ARMO Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by ArQule Inc, H2 2017
Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2017
Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2017
Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2017
Colorectal Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2017
Colorectal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2017
Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
Colorectal Cancer - Pipeline by Bayer AG, H2 2017
Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2017
Colorectal Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017
Colorectal Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by Biocon Ltd, H2 2017
Colorectal Cancer - Pipeline by Bionomics Ltd, H2 2017
Colorectal Cancer - Pipeline by Bionovis SA, H2 2017
Colorectal Cancer - Pipeline by Biotecnol Ltd, H2 2017
Colorectal Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2017
Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Colorectal Cancer - Pipeline by Boston Biomedical Inc, H2 2017
Colorectal Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Colorectal Cancer - Pipeline by Calithera Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by Cantargia AB, H2 2017
Colorectal Cancer - Pipeline by Carna Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2017
Colorectal Cancer - Pipeline by Celgene Corp, H2 2017
Colorectal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by Cellectar Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2017
Colorectal Cancer - Pipeline by Celltrion Inc, H2 2017
Colorectal Cancer - Pipeline by Celyad SA, H2 2017
Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017
Colorectal Cancer - Pipeline by ChoDang Pharm Co Ltd, H2 2017
Colorectal Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Colorectal Cancer - Pipeline by Cleave Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Cleveland BioLabs Inc, H2 2017
Colorectal Cancer - Pipeline by COARE Biotechnology Inc, H2 2017

List of Figures
Number of Products under Development for Colorectal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

【レポートのキーワード】

大腸癌

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[大腸癌:治療薬開発パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆